Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (6782)	2/20/2001 11:26:20 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Milestones accomplished: United Kingdom approval of Pennsaid Distribution partnership in the UK Initiation of reciprical agreement for Europe Massive financing agreement between 6.50 and 25.00 Completion of WF10 phase III clinical trials in US & Canada Milestones probable in near term: Launch of Pennsaid into the UK market in March Approval of Pennsaid in EU countries Distribution partnerships in Europe WF10 phase III results publication Launch of Pennsaid into the $2.5 billion (US) EU market Milestones remaining: Approval of Pennsaid in Canada Approval of Pennsaid in the US Distribution partnership in the US for Pennsaid Launch of Pennsaid in the US Approval of Pennsaid countries recognizing UK or US Nail fungus clinical trials North American approval of WF10 New carrier product studies Observations: Disease is unaffected by economic cycles. The arthritis market is expected to grow over 10% per year for over 10 years - more than doubling in 8 years. Thousands of people have used Pennsaid for years without a single serious side affect (some itching) while reporting strong results. Dimethaid is within a month of starting to produce revenue with a quality product in a multi billion dollar market.